6agx

The cocrystal structure of FGFR2 bound with compound 14 harboring 5H-pyrrolo[2,3-b]pyrazine scaffold

Method: X-RAY DIFFRACTION D_max: 149.2 Å Quality: GOOD

▼

1. 蛋白身份与相关结构 Protein Identity & Related Structures

Fibroblast growth factor receptor 2

Homo sapiens

当前结构中的状态

Assembly	聚集状态	构建体	突变与修饰	配体、离子与共同组分	实验方法与环境	结构质量
1	蛋白同源多聚体同源多聚体蛋白 × 2 PDB 声明：dimeric（2）与蛋白拷贝数一致	链 A； UniProt 467–764 链 B； UniProt 467–764	片段：UNP residues 467-764 突变：A628T 非标准单体：是（mmCIF未提供具体位点）	9WX ethyl [4-({3-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazin-5-yl}sulfonyl)-1H-imidazol-1-yl]acetate × 2	X-RAY DIFFRACTION X-ray结晶条件：EVAPORATION；pH 6.5；298 K；0.2M Ammonium sulfate, 0.1M MES pH 6.5, 30%(w/v) PEG 5000 MME	分辨率 2.95 Å R-free 0.298
2	蛋白同源多聚体同源多聚体蛋白 × 2 PDB 声明：dimeric（2）与蛋白拷贝数一致	链 C； UniProt 467–764 链 D； UniProt 467–764	片段：UNP residues 467-764 突变：A628T 非标准单体：是（mmCIF未提供具体位点）	9WX ethyl [4-({3-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazin-5-yl}sulfonyl)-1H-imidazol-1-yl]acetate × 2	X-RAY DIFFRACTION X-ray结晶条件：EVAPORATION；pH 6.5；298 K；0.2M Ammonium sulfate, 0.1M MES pH 6.5, 30%(w/v) PEG 5000 MME	分辨率 2.95 Å R-free 0.298

数据库中的同蛋白其他状态

以下每一行都是同一 UniProt 蛋白在另一个 PDB 条目中的 biological assembly， “相对当前条目”直接指出证据层面的不同；没有差异标签表示当前已读取字段一致。

其他 PDB	相对当前条目 6AGX	Assembly / 聚集状态	构建体	突变与修饰	配体、离子与非聚合物	实验方法与环境	结构质量
10OO FGFR2 mutant D650V with compound 4 (AZD3463) 提交 2026-01-29	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	突变：D650V	A1C65 (4P)-N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 8.5；293 K；30% PEG 4,000, 200 mM Lithium Sulfate, 100 mM TRIS pH 8.5	分辨率 1.85 Å R-free 0.256
10OO FGFR2 mutant D650V with compound 4 (AZD3463) 提交 2026-01-29	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	突变：D650V	A1C65 (4P)-N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 8.5；293 K；30% PEG 4,000, 200 mM Lithium Sulfate, 100 mM TRIS pH 8.5	分辨率 1.85 Å R-free 0.256
10OQ FGFR2 mutant D650V with compound 6 提交 2026-01-29	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	突变：D650V	A1C66 N-[(3M)-3-{5-chloro-2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}-1-methyl-1H-indol-6-yl]propanamide × 1 GOL GLYCEROL × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 5.6；293 K；22% PEG 4,000, 200 mM Ammonium Sulfate, 100 mM Sodium Citrate pH 5.6	分辨率 1.98 Å R-free 0.251
10OQ FGFR2 mutant D650V with compound 6 提交 2026-01-29	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	突变：D650V	A1C66 N-[(3M)-3-{5-chloro-2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}-1-methyl-1H-indol-6-yl]propanamide × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 5.6；293 K；22% PEG 4,000, 200 mM Ammonium Sulfate, 100 mM Sodium Citrate pH 5.6	分辨率 1.98 Å R-free 0.251
10OU FGFR2 mutant D650V with compound 12 提交 2026-01-29	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	突变：D650V	A1C67 N-[(3M)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1-methyl-1H-indol-6-yl]propanamide × 1 EDO 1,2-ETHANEDIOL × 11 GOL GLYCEROL × 4 SO4 SULFATE ION × 5	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 5.6；293 K；22% PEG 4,000, 200 mM Ammonium Sulfate, 100 mM Sodium Citrate pH 5.6	分辨率 1.77 Å R-free 0.213
10OU FGFR2 mutant D650V with compound 12 提交 2026-01-29	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	突变：D650V	A1C67 N-[(3M)-3-{2-[(1-ethyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1-methyl-1H-indol-6-yl]propanamide × 1 EDO 1,2-ETHANEDIOL × 11 GOL GLYCEROL × 8 SO4 SULFATE ION × 4	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 5.6；293 K；22% PEG 4,000, 200 mM Ammonium Sulfate, 100 mM Sodium Citrate pH 5.6	分辨率 1.77 Å R-free 0.213
1DJS LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1 提交 1999-12-03	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 4 PDB 声明：tetrameric	链 A 32–36（5 aa）片段：IG-LIKE DOMAINS 2 AND 3 链 A 152–362（211 aa）片段：IG-LIKE DOMAINS 2 AND 3	突变：N147T,S148L,N149E,N150P,K151E,R152G 非标准单体：是（mmCIF未提供具体位点）突变：N147T,S148L,N149E,N150P,K151E,R152G 非标准单体：是（mmCIF未提供具体位点）	SO4 SULFATE ION × 18	X-RAY DIFFRACTION X-ray结晶条件 pH 7.5；1.6M AMMONIUM SULFATE, 10MM TRIS (PH7.5), pH 7.50	分辨率 2.40 Å R-free 0.315
1DJS LIGAND-BINDING PORTION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 IN COMPLEX WITH FGF1 提交 1999-12-03	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白异源复合物异源复合物；蛋白 × 8 PDB 声明：octameric	链 A 32–36（5 aa）片段：IG-LIKE DOMAINS 2 AND 3 链 A 152–362（211 aa）片段：IG-LIKE DOMAINS 2 AND 3	突变：N147T,S148L,N149E,N150P,K151E,R152G 非标准单体：是（mmCIF未提供具体位点）突变：N147T,S148L,N149E,N150P,K151E,R152G 非标准单体：是（mmCIF未提供具体位点）	SO4 SULFATE ION × 36	X-RAY DIFFRACTION X-ray结晶条件 pH 7.5；1.6M AMMONIUM SULFATE, 10MM TRIS (PH7.5), pH 7.50	分辨率 2.40 Å R-free 0.315
1E0O CRYSTAL STRUCTURE OF A TERNARY FGF1-FGFR2-HEPARIN COMPLEX 提交 2000-04-03	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 其他组合异源复合物；蛋白 × 4 PDB 声明：pentameric	链 B 148–366（219 aa）链 D 148–366（219 aa）	未记录	NI NICKEL (II) ION × 5 SO4 SULFATE ION × 5	X-RAY DIFFRACTION X-ray结晶条件 pH 8.5；CRYSTALS WERE GROWN FROM: 1.0M LI2SO4, 0.1M TRISCL PH=8.5, 10MM NISO4, pH 8.50	分辨率 2.80 Å R-free 0.309
1EV2 CRYSTAL STRUCTURE OF FGF2 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 (FGFR2) 提交 2000-04-19	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 8 PDB 声明：octameric	链 E 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3) 链 F 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3) 链 G 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3) 链 H 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 2 CONSISTING OF IMMUNOGLOBULIN LIKE DOMAINS II (D2) AND III (D3)	未记录	SO4 SULFATE ION × 4	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, temperature 298.0K	分辨率 2.20 Å R-free 0.273
1GJO The FGFr2 tyrosine kinase domain 提交 2001-07-31	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 4 PDB 声明：tetrameric	链 A 456–768（313 aa）片段：TYROSINE KINASE DOMAIN RESIDUES 465-768	未记录	SO4 SULFATE ION × 8	X-RAY DIFFRACTION X-ray结晶条件 pH 5.9；32% AMMONIUM SULFATE, TRIS/MALEIC ACID BUFFER, PH 5.9	分辨率 2.40 Å R-free 0.256
1II4 CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 提交 2001-04-20	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 E 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366	突变：S252W	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K	分辨率 2.70 Å R-free 0.267
1II4 CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 提交 2001-04-20	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 F 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366	突变：S252W	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K	分辨率 2.70 Å R-free 0.267
1II4 CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 提交 2001-04-20	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 G 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366	突变：S252W	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K	分辨率 2.70 Å R-free 0.267
1II4 CRYSTAL STRUCTURE OF SER252TRP APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 提交 2001-04-20	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 H 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366	突变：S252W	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K	分辨率 2.70 Å R-free 0.267
1IIL CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 提交 2001-04-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 E 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366	突变：P253R	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K	分辨率 2.30 Å R-free 0.259
1IIL CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 提交 2001-04-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 F 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366	突变：P253R	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K	分辨率 2.30 Å R-free 0.259
1IIL CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 提交 2001-04-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 G 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366	突变：P253R	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K	分辨率 2.30 Å R-free 0.259
1IIL CRYSTAL STRUCTURE OF PRO253ARG APERT MUTANT FGF RECEPTOR 2 (FGFR2) IN COMPLEX WITH FGF2 提交 2001-04-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 H 147–366（220 aa）片段：EXTRACELLULAR LIGAND BINDING DOMAIN CONSISTING OF IG-LIKE DOMAINS II (D2) AND III (D3), RESIDUES 147-366	突变：P253R	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；PEG 4000, Isopropanol, HEPES-NaOH, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K	分辨率 2.30 Å R-free 0.259
1NUN Crystal Structure Analysis of the FGF10-FGFR2b Complex 提交 2003-01-31	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 B 140–369（230 aa）	非标准单体：是（mmCIF未提供具体位点）	SO4 SULFATE ION × 2 15P POLYETHYLENE GLYCOL (N=34) × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；PEG 400, ammonium sulfate, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.90 Å R-free 0.288
1OEC FGFr2 kinase domain 提交 2003-03-24	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 4 PDB 声明：tetrameric	链 A 456–768（313 aa）片段：TYROSINE KINASE DOMAIN, RESIDUES 456-768	未记录	SO4 SULFATE ION × 8 AA2 4-ARYL-2-PHENYLAMINO PYRIMIDINE × 4	X-RAY DIFFRACTION X-ray结晶条件 pH 5.9；pH 5.90	分辨率 2.40 Å R-free 0.285
2PSQ Crystal Structure of Unphosphorylated Unactivated Wild Type FGF Receptor 2 (FGFR2) Kinase Domain 提交 2007-05-07	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 413–768（356 aa）片段：Kinase Domain 链 B 413–768（356 aa）片段：Kinase Domain	未记录	SO4 SULFATE ION × 4	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 20% PEG 4000, 200mM (NH4)2SO4, 3% C2H4O, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.40 Å R-free 0.258
2PVF Crystal Structure of Tyrosine Phosphorylated Activated FGF Receptor 2 (FGFR2) Kinase Domain in Complex with ATP Analog and Substrate Peptide 提交 2007-05-09	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–778（321 aa）片段：human FGF Receptor 2 Kinase Domain 链 B 764–778（15 aa）片段：Peptide Stubstrate	突变：C491A 非标准单体：是（mmCIF未提供具体位点）	MG MAGNESIUM ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 27% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.80 Å R-free 0.265
2PVY Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome. 提交 2007-05-10	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 4 PDB 声明：tetrameric	链 A 458–768（311 aa）片段：Kinase Domain 链 B 458–768（311 aa）片段：Kinase Domain 链 C 458–768（311 aa）片段：Kinase Domain 链 D 458–768（311 aa）片段：Kinase Domain	突变：C491A, K659N 突变：C491A, K659N 突变：C491A, K659N 突变：C491A, K659N	SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 4	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.20 Å R-free 0.276
2PWL Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549H Mutation Responsible for Crouzon Syndrome. 提交 2007-05-11	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Kinase Domain 链 B 458–768（311 aa）片段：Kinase Domain	突变：C491A, N549H 突变：C491A, N549H	SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 8% C3H5(OH)3, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.40 Å R-free 0.238
2PY3 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565G Mutation Responsible for Pfeiffer Syndrome 提交 2007-05-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Kinase Domain 链 B 458–768（311 aa）片段：Kinase Domain	突变：C491A, E565G 突变：C491A, E565G	SO4 SULFATE ION × 4 MG MAGNESIUM ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 2% C3H5(OH)3, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.30 Å R-free 0.252
2PZ5 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic N549T Mutation Responsible for Pfeiffer Syndrome 提交 2007-05-17	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Kinase Domain 链 B 458–768（311 aa）片段：Kinase Domain	突变：C491A, N549T 突变：C491A, N549T	SO4 SULFATE ION × 4 MG MAGNESIUM ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.40 Å R-free 0.254
2PZP Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K526E Mutation Responsible for Crouzon Syndrome 提交 2007-05-18	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Kinase Domain 链 B 458–768（311 aa）片段：Kinase Domain	突变：C491A, K526E 突变：C491A, K526E	SO4 SULFATE ION × 4 MG MAGNESIUM ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.40 Å R-free 0.251
2PZR Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K641R Mutation Responsible for Pfeiffer Syndrome 提交 2007-05-18	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Kinase Domain 链 B 458–768（311 aa）片段：Kinase Domain	突变：C491A, K641R 突变：C491A, K641R	SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 28% PEG 4000, 300mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 3.00 Å R-free 0.268
2Q0B Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic E565A Mutation Responsible for Pfeiffer Syndrome 提交 2007-05-21	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Kinase Domain 链 B 458–768（311 aa）片段：Kinase Domain	突变：C491A, E565A 突变：C491A, E565A	SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 19% PEG 4000, 300mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.90 Å R-free 0.252
3B2T Structure of phosphotransferase 提交 2007-10-19	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 4 PDB 声明：tetrameric	链 A 458–768（311 aa）片段：UNP residues 458-768 链 B 458–768（311 aa）片段：UNP residues 458-768	突变：A628T, E767Q 突变：A628T, E767Q	PO4 PHOSPHATE ION × 8 M33 5'-O-[(S)-hydroxy{[(S)-hydroxy(methyl)phosphoryl]oxy}phosphoryl]adenosine × 4	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.6M sodium dihydrogen phosphate, 0.6M potassium dihydrogen phosphate, 0.1M HEPES, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 277K	分辨率 1.80 Å R-free 0.233
3B2T Structure of phosphotransferase 提交 2007-10-19	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：UNP residues 458-768 链 B 458–768（311 aa）片段：UNP residues 458-768	突变：A628T, E767Q 突变：A628T, E767Q	PO4 PHOSPHATE ION × 4 M33 5'-O-[(S)-hydroxy{[(S)-hydroxy(methyl)phosphoryl]oxy}phosphoryl]adenosine × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8；277 K；0.6M sodium dihydrogen phosphate, 0.6M potassium dihydrogen phosphate, 0.1M HEPES, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 277K	分辨率 1.80 Å R-free 0.233
3CAF Crystal Structure of hFGFR2 D2 Domain 提交 2008-02-19	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 150–249（100 aa）片段：Ig-like C2-type 2	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；20%(w/v) PEG3350, 0.1M (NH3)2SO4, 100mM HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.96 Å R-free 0.275
3CAF Crystal Structure of hFGFR2 D2 Domain 提交 2008-02-19	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 150–249（100 aa）片段：Ig-like C2-type 2	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；20%(w/v) PEG3350, 0.1M (NH3)2SO4, 100mM HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.96 Å R-free 0.275
3CLY Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domains Trapped in Trans-Phosphorylation Reaction 提交 2008-03-20	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–778（321 aa）片段：Protein Kinase Domain	突变：C491A 非标准单体：是（mmCIF未提供具体位点）	MG MAGNESIUM ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100 mM HEPES pH7.5, 26% PEG 4000, 200 mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.00 Å R-free 0.247
3CLY Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domains Trapped in Trans-Phosphorylation Reaction 提交 2008-03-20	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–778（321 aa）片段：Protein Kinase Domain	突变：C491A 非标准单体：是（mmCIF未提供具体位点）	MG MAGNESIUM ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100 mM HEPES pH7.5, 26% PEG 4000, 200 mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.00 Å R-free 0.247
3CU1 Crystal Structure of 2:2:2 FGFR2D2:FGF1:SOS complex 提交 2008-04-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 其他组合异源复合物；蛋白 × 4 PDB 声明：tetrameric	链 A 150–249（100 aa）片段：Ig-like C2-type 2 domain, UNP residues 150-249 链 C 150–249（100 aa）片段：Ig-like C2-type 2 domain, UNP residues 150-249	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；12% PEG3350, 4% Tacsimate, pH 7.0, vapor diffusion, hanging drop, temperature 298.0K	分辨率 2.60 Å R-free 0.277
3DAR Crystal structure of D2 domain from human FGFR2 提交 2008-05-30	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 146–249（104 aa）片段：D2 domain, Ig-like C2-type 2, UNP residues 146-249	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；0.2 M sodium acetate, 0.1 M Tris-HCl, 30% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K, pH 8.5	分辨率 2.20 Å R-free 0.255
3DAR Crystal structure of D2 domain from human FGFR2 提交 2008-05-30	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 146–249（104 aa）片段：D2 domain, Ig-like C2-type 2, UNP residues 146-249	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；0.2 M sodium acetate, 0.1 M Tris-HCl, 30% PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 291.0K, pH 8.5	分辨率 2.20 Å R-free 0.255
3EUU Crystal structure of the FGFR2 D2 domain 提交 2008-10-10	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 150–249（100 aa）片段：UNP residues 150-249	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.8M ammonium citrate dibasic, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K	分辨率 2.34 Å R-free 0.228
3EUU Crystal structure of the FGFR2 D2 domain 提交 2008-10-10	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 150–249（100 aa）片段：UNP residues 150-249	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.8M ammonium citrate dibasic, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K	分辨率 2.34 Å R-free 0.228
3EUU Crystal structure of the FGFR2 D2 domain 提交 2008-10-10	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 150–249（100 aa）片段：UNP residues 150-249 链 B 150–249（100 aa）片段：UNP residues 150-249	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.8M ammonium citrate dibasic, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K	分辨率 2.34 Å R-free 0.228
3OJ2 Crystal structure of FGF1 complexed with the ectodomain of FGFR2b harboring the A172F Pfeiffer syndrome mutation 提交 2010-08-20	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 C 140–313（174 aa）	突变：A172F	SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes, 20% PEG4000, 0.2M ammonium sulfate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K	分辨率 2.20 Å R-free 0.294
3OJ2 Crystal structure of FGF1 complexed with the ectodomain of FGFR2b harboring the A172F Pfeiffer syndrome mutation 提交 2010-08-20	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 D 140–313（174 aa）	突变：A172F	SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes, 20% PEG4000, 0.2M ammonium sulfate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K	分辨率 2.20 Å R-free 0.294
3OJM Crystal Structure of FGF1 complexed with the ectodomain of FGFR2b harboring P253R Apert mutation 提交 2010-08-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 B 140–313（174 aa）片段：FGFR2b	突变：P253R	SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes, 22% monomethyl ether PEG5000, 0.2M ammonium sulfate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K	分辨率 2.10 Å R-free 0.263
3RI1 Crystal structure of the catalytic domain of FGFR2 kinase in complex with ARQ 069 提交 2011-04-12	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）片段：UNP residues 458-768	未记录	3RH (6S)-6-phenyl-5,6-dihydrobenzo[h]quinazolin-2-amine × 1 SO4 SULFATE ION × 5	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；15% polyethylene glycol 4000 and 0.3M lithium sulfate and 100 mM HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.10 Å R-free 0.247
3RI1 Crystal structure of the catalytic domain of FGFR2 kinase in complex with ARQ 069 提交 2011-04-12	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）片段：UNP residues 458-768	未记录	3RH (6S)-6-phenyl-5,6-dihydrobenzo[h]quinazolin-2-amine × 1 SO4 SULFATE ION × 4	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；15% polyethylene glycol 4000 and 0.3M lithium sulfate and 100 mM HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.10 Å R-free 0.247
4J23 Low resolution crystal structure of the FGFR2D2D3/FGF1/SR128545 complex 提交 2013-02-04	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 147–366（220 aa）片段：unp residues 147-366	未记录	未记录非水小分子	X-RAY DIFFRACTION mmCIF 未提供已读取条件	分辨率 3.88 Å R-free 0.384
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659N	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659N	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659N	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659N	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. 提交 2013-02-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 5 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768) 链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659N 突变：C491A, K659N	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.38 Å R-free 0.255
4J95 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic K659N Mutation Responsible for an Unclassified Craniosynostosis Syndrome in Space Group C2. 提交 2013-02-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 6 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 C 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768) 链 D 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659N 突变：C491A, K659N	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 SO4 SULFATE ION × 4	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 3% v/v CH3CH2OH, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.38 Å R-free 0.255
4J96 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659M	SO4 SULFATE ION × 1 FLC CITRATE ANION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.30 Å R-free 0.219
4J96 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659M	SO4 SULFATE ION × 2 FLC CITRATE ANION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.30 Å R-free 0.219
4J96 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659M Mutation Identified in Cervical Cancer. 提交 2013-02-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768) 链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659M 突变：C491A, K659M	SO4 SULFATE ION × 3 FLC CITRATE ANION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.30 Å R-free 0.219
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659E	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659E	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659E	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659E	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. 提交 2013-02-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 5 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768) 链 C 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659E 突变：C491A, K659E	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.55 Å R-free 0.257
4J97 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Pathogenic Gain-of-Function K659E Mutation Identified in Endometrial Cancer. 提交 2013-02-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 6 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768) 链 D 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659E 突变：C491A, K659E	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.55 Å R-free 0.257
4J98 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659Q Mutation. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659Q	SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.31 Å R-free 0.234
4J98 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659Q Mutation. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659Q	SO4 SULFATE ION × 3 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.31 Å R-free 0.234
4J98 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659Q Mutation. 提交 2013-02-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768) 链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659Q 突变：C491A, K659Q	SO4 SULFATE ION × 5 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM HOC(COONa)(CH2COONa)2, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 2.31 Å R-free 0.234
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659T	SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659T	SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659T	SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. 提交 2013-02-15	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659T	SO4 SULFATE ION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. 提交 2013-02-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 5 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768) 链 B 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659T 突变：C491A, K659T	SO4 SULFATE ION × 4 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.85 Å R-free 0.240
4J99 Crystal Structure of FGF Receptor 2 (FGFR2) Kinase Domain Harboring the Gain-of-Function K659T Mutation. 提交 2013-02-15	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 6 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 C 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768) 链 D 458–768（311 aa）片段：Human FGF Receptor 2 Kinase Domain (UNP Residues 458-768)	突变：C491A, K659T 突变：C491A, K659T	SO4 SULFATE ION × 3 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 MG MAGNESIUM ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM HEPES pH7.5, 25% PEG 4000, 200mM (NH4)2SO4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K	分辨率 1.85 Å R-free 0.240
4WV1 Crystal structure of the FGFR2 D2 domain in complex with Fab 2B.1.3 提交 2014-11-04	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 3 PDB 声明：trimeric	链 F 153–251（99 aa）片段：UNP residues 153-251	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；292 K；PEG 3350, potassium nitrate	分辨率 2.36 Å R-free 0.244
4WV1 Crystal structure of the FGFR2 D2 domain in complex with Fab 2B.1.3 提交 2014-11-04	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白异源复合物异源复合物；蛋白 × 3 PDB 声明：trimeric	链 C 153–251（99 aa）片段：UNP residues 153-251	未记录	未记录非水小分子	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；292 K；PEG 3350, potassium nitrate	分辨率 2.36 Å R-free 0.244
5EG3 Crystal Structure of the Activated FGF Receptor 2 (FGFR2) Kinase Domain in complex with the cSH2 domain of Phospholipase C gamma (PLCgamma) 提交 2015-10-26	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白异源复合物异源复合物；蛋白 × 2 PDB 声明：dimeric	链 A 458–778（321 aa）片段：UNP residues 458-778	突变：Y466F, C491A, E565A, Y586L, Y588P, Y656F, Y657F, K659E 非标准单体：是（mmCIF未提供具体位点）	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；277 K；25 mM HEPES (pH 7.5), PEG20000 (12% 18%) and 2% (w/v) Benzamidine hydrochloride	分辨率 2.61 Å R-free 0.237
5UGL Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation 提交 2017-01-09	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 341–651（311 aa）片段：UNP residues 341-651	突变：D650V	SO4 SULFATE ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；25 mM HEPES pH7.5, 15%-25% w/v PEG4000, 0.2-0.3 M NH4SO3	分辨率 1.86 Å R-free 0.258
5UGL Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation 提交 2017-01-09	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 341–651（311 aa）片段：UNP residues 341-651	突变：D650V	SO4 SULFATE ION × 1 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；25 mM HEPES pH7.5, 15%-25% w/v PEG4000, 0.2-0.3 M NH4SO3	分辨率 1.86 Å R-free 0.258
5UGX Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 Harboring a E565A/D650V double Gain-of-Function Mutation 提交 2017-01-10	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 341–651（311 aa）片段：UNP residues 341-651	突变：E565A, D650V	SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；25 mM HEPES (pH 7.5), 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium sulfate	分辨率 2.35 Å R-free 0.275
5UGX Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 Harboring a E565A/D650V double Gain-of-Function Mutation 提交 2017-01-10	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 341–651（311 aa）片段：UNP residues 341-651	突变：E565A, D650V	SO4 SULFATE ION × 2 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；25 mM HEPES (pH 7.5), 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium sulfate	分辨率 2.35 Å R-free 0.275
5UHN Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring a N549H/E565A Double Gain-of-Function Mutation 提交 2017-01-11	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 342–652（311 aa）片段：UNP residues 342-652	突变：N549H, E565A	SO4 SULFATE ION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；25 mM HEPES (pH 7.5), 15-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate	分辨率 2.91 Å R-free 0.311
5UHN Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring a N549H/E565A Double Gain-of-Function Mutation 提交 2017-01-11	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 342–652（311 aa）片段：UNP residues 342-652	突变：N549H, E565A	SO4 SULFATE ION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；25 mM HEPES (pH 7.5), 15-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate	分辨率 2.91 Å R-free 0.311
5UI0 Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring an E565A/K659M Double Gain-of-Function Mutation 提交 2017-01-12	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 341–651（311 aa）片段：UNP residues 341-651	突变：E565A, K659M	FLC CITRATE ANION × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；25 mM HEPES pH 7.5, 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate	分辨率 2.05 Å R-free 0.207
5UI0 Crystal Structure of the Tyrosine Kinase Domain of FGF Receptor 2 harboring an E565A/K659M Double Gain-of-Function Mutation 提交 2017-01-12	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 341–651（311 aa）片段：UNP residues 341-651	突变：E565A, K659M	FLC CITRATE ANION × 1 ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293 K；25 mM HEPES pH 7.5, 15%-25% w/v PEG 4000, 0.2-0.3 M Ammonium Sulfate	分辨率 2.05 Å R-free 0.207
6LVK Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative 提交 2020-02-04	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 459–768（310 aa）	非标准单体：是（mmCIF未提供具体位点）	EVC N-ethyl-2-[[4-[[4-(4-methylpiperazin-1-yl)-3-(2-morpholin-4-ylethoxy)phenyl]amino]-1,3,5-triazin-2-yl]amino]benzenesulfonamide × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；296 K；Tris, Ammonium sulfate, PEG 8000	分辨率 2.29 Å R-free 0.247
6LVK Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative 提交 2020-02-04	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 459–768（310 aa）	非标准单体：是（mmCIF未提供具体位点）	EVC N-ethyl-2-[[4-[[4-(4-methylpiperazin-1-yl)-3-(2-morpholin-4-ylethoxy)phenyl]amino]-1,3,5-triazin-2-yl]amino]benzenesulfonamide × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；296 K；Tris, Ammonium sulfate, PEG 8000	分辨率 2.29 Å R-free 0.247
6LVL Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative 提交 2020-02-04	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 459–768（310 aa）	未记录	SO4 SULFATE ION × 1 EVL N-ethyl-2-[[4-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-1,3,5-triazin-2-yl]amino]benzenesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；296 K；Tris, Ammonium sulfate, PEG 8000	分辨率 2.98 Å R-free 0.251
6LVL Crystal structure of FGFR2 in complex with 1,3,5-triazine derivative 提交 2020-02-04	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 459–768（310 aa）	未记录	SO4 SULFATE ION × 3 EVL N-ethyl-2-[[4-[[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-1,3,5-triazin-2-yl]amino]benzenesulfonamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 8.5；296 K；Tris, Ammonium sulfate, PEG 8000	分辨率 2.98 Å R-free 0.251
6V6Q Crystal Structure of Monophosphorylated FGF Receptor 2 isoform IIIb with PTR657 提交 2019-12-05	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 413–821（409 aa）链 B 413–821（409 aa）	突变：Y467F,Y562F,Y576F,Y587F,Y589F,Y609F,Y617F,Y658F,Y734F 非标准单体：是（mmCIF未提供具体位点）突变：Y467F,Y562F,Y576F,Y587F,Y589F,Y609F,Y617F,Y658F,Y734F 非标准单体：是（mmCIF未提供具体位点）	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 MG MAGNESIUM ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；160mM TMAO, 20% PEG 2000, 100mM Tris pH 8.6	分辨率 2.46 Å R-free 0.239
6V6Q Crystal Structure of Monophosphorylated FGF Receptor 2 isoform IIIb with PTR657 提交 2019-12-05	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 C 413–821（409 aa）链 D 413–821（409 aa）	突变：Y467F,Y562F,Y576F,Y587F,Y589F,Y609F,Y617F,Y658F,Y734F 非标准单体：是（mmCIF未提供具体位点）突变：Y467F,Y562F,Y576F,Y587F,Y589F,Y609F,Y617F,Y658F,Y734F 非标准单体：是（mmCIF未提供具体位点）	ACP PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER × 2 MG MAGNESIUM ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8.6；293 K；160mM TMAO, 20% PEG 2000, 100mM Tris pH 8.6	分辨率 2.46 Å R-free 0.239
7KIA Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 19 提交 2020-10-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 461–768（308 aa）片段：Kinase domain, residues 461-768	突变：V564F	WFD 1-[4-(4-{4-(4-methylpiperazin-1-yl)-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}phenyl)piperidin-1-yl]prop-2-en-1-one × 1 FLC CITRATE ANION × 1 NA SODIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；12% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0	分辨率 2.22 Å R-free 0.223
7KIA Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 19 提交 2020-10-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 461–768（308 aa）片段：Kinase domain, residues 461-768	突变：V564F	WFD 1-[4-(4-{4-(4-methylpiperazin-1-yl)-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}phenyl)piperidin-1-yl]prop-2-en-1-one × 1 FLC CITRATE ANION × 1 NA SODIUM ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；12% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0	分辨率 2.22 Å R-free 0.223
7KIE Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 3 提交 2020-10-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 461–768（308 aa）片段：Kinase domain, residues 461-768	突变：V564F	WF7 N-{4-[(E)-2-{4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}ethenyl]phenyl}prop-2-enamide × 1 FLC CITRATE ANION × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；15% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0	分辨率 2.47 Å R-free 0.229
7KIE Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with covalent compound 3 提交 2020-10-23	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 461–768（308 aa）片段：Kinase domain, residues 461-768	突变：V564F	WF7 N-{4-[(E)-2-{4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}ethenyl]phenyl}prop-2-enamide × 1 FLC CITRATE ANION × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 4；298 K；15% w/v PEG 8000, 0.1M Sodium Citrate pH 4.0	分辨率 2.47 Å R-free 0.229
7OZY FGFR2 kinase domain (residues 461-763) in complex with 38. 提交 2021-06-29	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 AAA 465–763（299 aa）	未记录	47I 4-[3-(4-piperazin-4-ium-1-ylphenyl)-1H-indazol-6-yl]phenol × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.6；291 K；25% w/v PEG 3350, 0.1 M ammonium sulfate, 0.1 M HEPES	分辨率 2.28 Å R-free 0.296
7OZY FGFR2 kinase domain (residues 461-763) in complex with 38. 提交 2021-06-29	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 BBB 465–763（299 aa）	未记录	47I 4-[3-(4-piperazin-4-ium-1-ylphenyl)-1H-indazol-6-yl]phenol × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 7.6；291 K；25% w/v PEG 3350, 0.1 M ammonium sulfate, 0.1 M HEPES	分辨率 2.28 Å R-free 0.296
8E1X FGFR2 kinase domain in complex with a Pyrazolo[1,5-a]pyrimidine analog (Compound 29) 提交 2022-08-11	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 459–768（310 aa）链 B 459–768（310 aa）	非标准单体：是（mmCIF未提供具体位点）非标准单体：是（mmCIF未提供具体位点）	U9P (5M)-N-methyl-5-{(6M,8S)-5-{[(3S)-oxolan-3-yl]amino}-6-[1-(propan-2-yl)-1H-pyrazol-3-yl]pyrazolo[1,5-a]pyrimidin-3-yl}pyridine-3-carboxamide × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 5.2；293 K；0.1 M Sodium citrate pH 5.2; 28% w/w PEG 4,000; 0.2 M Ammonium acetate	分辨率 2.68 Å R-free 0.272
8H75 FGFR2 in complex with YJ001 提交 2022-10-19	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 4 PDB 声明：tetrameric	链 A 347–656（310 aa）链 B 347–656（310 aa）链 C 347–656（310 aa）链 D 347–656（310 aa）	非标准单体：是（mmCIF未提供具体位点）非标准单体：是（mmCIF未提供具体位点）非标准单体：是（mmCIF未提供具体位点）非标准单体：是（mmCIF未提供具体位点）	KX0 Tinengotinib × 4 CL CHLORIDE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；0.2M (NH4)2SO4, 0.1M Bis-Tris pH6.0, 25% PEG3350.	分辨率 3.75 Å R-free 0.238
8STG Discovery and clinical validation of RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations 提交 2023-05-10	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–769（312 aa）片段：kinase domain (UNP residues 458-769)	未记录	WCJ N-{4-[(5P)-4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-2-methylpropanamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8；291.15 K；0.1 M Tris, pH 8, 18-20% w/v PEG8000	分辨率 3.79 Å R-free 0.311
8STG Discovery and clinical validation of RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations 提交 2023-05-10	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–769（312 aa）片段：kinase domain (UNP residues 458-769)	未记录	WCJ N-{4-[(5P)-4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}-2-methylpropanamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 8；291.15 K；0.1 M Tris, pH 8, 18-20% w/v PEG8000	分辨率 3.79 Å R-free 0.311
8SWE FGFR2 Kinase Domain Bound to Reversible Inhibitor Cmpd 3 提交 2023-05-18	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	未记录	GOL GLYCEROL × 1 GSH Glutathione × 1 WXQ N-{4-[4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}prop-2-enamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；291.15 K；27 % PEG 4000, 0.1 M Hepes pH7.5, 0.252 M Ammonium Sulfate, 0.05 M GSH GSSG	分辨率 2.24 Å R-free 0.250
8SWE FGFR2 Kinase Domain Bound to Reversible Inhibitor Cmpd 3 提交 2023-05-18	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	未记录	GOL GLYCEROL × 3 WXQ N-{4-[4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}prop-2-enamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；291.15 K；27 % PEG 4000, 0.1 M Hepes pH7.5, 0.252 M Ammonium Sulfate, 0.05 M GSH GSSG	分辨率 2.24 Å R-free 0.250
8U1F FGFR2 Kinase Domain Bound to Irreversible Inhibitor Cmpd 10 提交 2023-08-31	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 458–768（311 aa）链 B 458–768（311 aa）	未记录	GOL GLYCEROL × 1 UIM N-[4-(4-amino-7-methyl-5-{4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]-2-methylpropanamide × 2 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；0.1 M Tris pH 8, 18% PEG K	分辨率 3.33 Å R-free 0.295
8W2X TAS-120 covalent structure with FGFR2 提交 2024-02-21	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	突变：D650V	A1AFR 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]propan-1-one × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2 M Potassium sodium tartrate tetrahydrate 2.0 M Ammonium sulfate 0.1 M Sodium citrate 5.6	分辨率 2.98 Å R-free 0.237
8W2X TAS-120 covalent structure with FGFR2 提交 2024-02-21	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	突变：D650V	A1AFR 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]propan-1-one × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 5.6；293 K；0.2 M Potassium sodium tartrate tetrahydrate 2.0 M Ammonium sulfate 0.1 M Sodium citrate 5.6	分辨率 2.98 Å R-free 0.237
8W38 TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	突变：N549D, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH 7.5	分辨率 2.60 Å R-free 0.359
8W38 TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	突变：N549D, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH 7.5	分辨率 2.60 Å R-free 0.359
8W38 TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 458–768（311 aa）	突变：N549D, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH 7.5	分辨率 2.60 Å R-free 0.359
8W38 TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 458–768（311 aa）	突变：N549D, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH 7.5	分辨率 2.60 Å R-free 0.359
8W3B TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	突变：N549H, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.2；291 K；0.2 M Lithium sulfate, 0.1 M HEPES 7.2, 25 % v/v PEG Smear Broad	分辨率 2.23 Å R-free 0.312
8W3B TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	突变：N549H, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.2；291 K；0.2 M Lithium sulfate, 0.1 M HEPES 7.2, 25 % v/v PEG Smear Broad	分辨率 2.23 Å R-free 0.312
8W3B TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 458–768（311 aa）	突变：N549H, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.2；291 K；0.2 M Lithium sulfate, 0.1 M HEPES 7.2, 25 % v/v PEG Smear Broad	分辨率 2.23 Å R-free 0.312
8W3B TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 458–768（311 aa）	突变：N549H, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.2；291 K；0.2 M Lithium sulfate, 0.1 M HEPES 7.2, 25 % v/v PEG Smear Broad	分辨率 2.23 Å R-free 0.312
8W3D TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	突变：N549K, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.2 M Lithium sulfate 0.1 M Bis-Tris 6.5 25 % w/v PEG 3350	分辨率 2.04 Å R-free 0.250
8W3D TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	突变：N549K, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.2 M Lithium sulfate 0.1 M Bis-Tris 6.5 25 % w/v PEG 3350	分辨率 2.04 Å R-free 0.250
8W3D TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 3 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 C 458–768（311 aa）	突变：N549K, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 SO4 SULFATE ION × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.2 M Lithium sulfate 0.1 M Bis-Tris 6.5 25 % w/v PEG 3350	分辨率 2.04 Å R-free 0.250
8W3D TAS-120 covalent structure with FGFR2 molecular brake mutant 提交 2024-02-22	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 4 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 D 458–768（311 aa）	突变：N549K, D650V	TZ0 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 3	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；0.2 M Lithium sulfate 0.1 M Bis-Tris 6.5 25 % w/v PEG 3350	分辨率 2.04 Å R-free 0.250
9U3N Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with compound LC-F2-01 提交 2025-03-18	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 458–768（311 aa）	突变：V564F	A1ENT ~{N}-[4-[4-azanyl-7-methyl-5-[2-(3-methylimidazo[4,5-b]pyridin-6-yl)ethynyl]pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]prop-2-enamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；291 K；0.2M Sodium formate, 20% PEG3,3500+16% Glutaric acid, 0.16% Mellitic acid, 0.16% Oxalic acid, 0.16% Pimelic acid, 0.16% Sebacic acid,0.16% trans-Cinnamic acid, 0.02 M HEPES Na pH6.8	分辨率 3.25 Å R-free 0.342
9U3N Crystal structure of FGFR2 kinase domain gatekeeper mutant V564F in complex with compound LC-F2-01 提交 2025-03-18	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 458–768（311 aa）	突变：V564F	A1ENT ~{N}-[4-[4-azanyl-7-methyl-5-[2-(3-methylimidazo[4,5-b]pyridin-6-yl)ethynyl]pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]prop-2-enamide × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP；291 K；0.2M Sodium formate, 20% PEG3,3500+16% Glutaric acid, 0.16% Mellitic acid, 0.16% Oxalic acid, 0.16% Pimelic acid, 0.16% Sebacic acid,0.16% trans-Cinnamic acid, 0.02 M HEPES Na pH6.8	分辨率 3.25 Å R-free 0.342
9U7E FGFR2 kinase domain with a macrocyclic compound 8g 提交 2025-03-24	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 465–768（304 aa）链 B 465–768（304 aa）	未记录	A1EOH (E)-4-methyl-17-(1-methyl-1H-pyrazol-4-yl)-7,10-dioxa-4-aza-1(3,6)-imidazo[1,2-b]pyridazina-2(3,5)-pyridinacyclodecaphan-3-one × 2 SO4 SULFATE ION × 2	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293.15 K；16% PEG 3350, 100 mM (NH4)2SO4, 100 mM HEPES, pH 7.5	分辨率 2.20 Å R-free 0.312
9U7S FGFR2 kinase domain with a macrocyclic compound 8r 提交 2025-03-25	构建体不同突变/修饰不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白同源多聚体同源多聚体；蛋白 × 2 PDB 声明：dimeric	链 A 465–768（304 aa）链 B 465–768（304 aa）	未记录	A1EOJ (E)-4-methyl-17-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-7,10-dioxa-4-aza-1(3,6)-imidazo[1,2-b]pyridazina-2(1,3)-benzenacyclodecaphan-3-one × 2 SO4 SULFATE ION × 6	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；293.15 K；18% PEG 3350, 100 mM (NH4)2SO4, 100 mM HEPES, pH 7.5	分辨率 1.99 Å R-free 0.225
9VLM The X-RAY co-crystal structure of human FGFR2 and covalent inhibitor 10a 提交 2025-06-25	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 1 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 A 465–765（301 aa）	未记录	A1ESP ~{N}-[3-[2-[[3-[2-(dimethylamino)ethylsulfamoylmethyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-indol-6-yl]propanamide × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；22% (w/v) PEG 8000, and 0.1 M Tris-HCl, pH 8.0	分辨率 2.26 Å R-free 0.254
9VLM The X-RAY co-crystal structure of human FGFR2 and covalent inhibitor 10a 提交 2025-06-25	构建体不同突变/修饰不同聚集状态不同配体/离子不同实验环境不同结构质量不同	Assembly 2 蛋白单体单体；蛋白 × 1 PDB 声明：monomeric	链 B 465–765（301 aa）	未记录	A1ESP ~{N}-[3-[2-[[3-[2-(dimethylamino)ethylsulfamoylmethyl]phenyl]amino]pyrimidin-4-yl]-1-methyl-indol-6-yl]propanamide × 1 GOL GLYCEROL × 1	X-RAY DIFFRACTION X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；22% (w/v) PEG 8000, and 0.1 M Tris-HCl, pH 8.0	分辨率 2.26 Å R-free 0.254

共 60 个其他 PDB 条目、122 个 assembly。打开独立比较页并筛选聚集状态

查看构建体与数据证据

UniProt名称	FGFR2_HUMAN
Isoform	—
PDB实体	1
链与序列区间	作者链 A； PDB构建体 1–298； UniProt 467–764 作者链 B； PDB构建体 1–298； UniProt 467–764 作者链 C； PDB构建体 1–298； UniProt 467–764 作者链 D； PDB构建体 1–298； UniProt 467–764

页面优先展示蛋白身份、当前 assembly、共同组分、聚集状态和跨 PDB 结构链接。链映射与序列区间收在“数据证据”中；数据库内部编号、导入时间和 assembly 操作表达式仅用于维护，因此不在读者页面展示。

SAXS 散射曲线 SAXS Profile

P(r) 距离分布 P(r) Distribution

下载 Download SAXS (.dat) P(r) (.pr.out) CIF

▼

2. 结构基本信息 2. Structure Basics

条目编号 entry_id	6agx
沉积日期 deposition_date	2018-08-15
结构标题 title	The cocrystal structure of FGFR2 bound with compound 14 harboring 5H-pyrrolo[2,3-b]pyrazine scaffold
关键词 keywords	Tyrosine-protein kinase, TRANSFERASE-INHIBITOR complex; TRANSFERASE/INHIBITOR
实验方法 method	X-RAY DIFFRACTION

▼

3. SAXS 参数 (CRYSOL 理论计算) 3. SAXS Parameters (CRYSOL)

回转半径 Rg (Guinier) rg_guinier	43.54 Å
回转半径 Rg (电子) rg_electron	43.99 Å
零角强度 I(0) i0	277905000.00
分子量 molecular_weight	136230.0 kDa
排除体积 excluded_volume	170420 Å³
包络体积 envelope_volume	231940 Å³
水化壳体积 shell_volume	46922 Å³
包络直径 envelope_diameter	156.2 Å
壳层 Rg shell_rg	44.71 Å
包络 Rg envelope_rg	43.52 Å
形状 Rg shape_rg	43.99 Å
总 Rg total_rg	44.04 Å
总原子数 total_atoms	9520
残基数 n_residues	1155
球谐函数阶数 n_harmonics	20
q 范围 q_range	— – 0.5000 Å⁻¹
数据点数 n_points	101
壳层类型 shell_type	directional
溶剂电子密度 solvent_density	0.3340 e/Å³
壳层衬度 contrast_shell	0.0300 e/Å³
CRYSOL 版本 crysol_version	4.1.3

▼

4. P(r) 距离分布 (GNOM 反演) 4. P(r) Analysis (GNOM)

最大尺寸 Dmax dmax	149.2 Å
Rg (实空间) rg_real	44.02 Å
Rg 误差 (实空间) rg_real_error	1.62 Å
I(0) (实空间) i0_real	2.7790e+08
I(0) 误差 (实空间) i0_real_error	5.1480e+06
Rg (倒空间) rg_reciprocal	43.55 Å
I(0) (倒空间) i0_reciprocal	277800000.0000
解质量估计 total_estimate	0.7623
解质量评级 solution_quality	GOOD a GOOD solution
P(r) 峰数 n_peaks	2
主峰位置 r_peak_primary	37.3 Å
偏度 Skewness skewness	0.523
峰度 Kurtosis kurtosis	-0.581
角度范围 angular_range	— – 0.1800 Å⁻¹
当前正则化参数 α current_alpha	0.0000
最高正则化参数 α highest_alpha	37420000.0000
实空间数据点数 n_real_points	37
GNOM 版本 gnom_version	4.1.3
质量判据 quality_criteria	AN1: 0.000; Oscil: 0.563; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.621; Smooth: 0.597

▶

5. 晶体学与实验 5. Crystallography & Experiment

▶

6. 实体与聚合物信息 Entities & Polymers (2)

实体 1 Entity 1 polymer

描述 description	Fibroblast growth factor receptor 2
分子量 formula_weight	34549.5 kDa
EC 编号 ec_number	2.7.10.1
突变 mutation	A628T
来源方法 src_method	man
拷贝数 entity_count	4

聚合物 Polymer

聚合物类型 type	polypeptide(L)
链编号 strand_id	A,B,C,D
原子数 atom_count	9544

ELPEDPKWEFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLASQKCIHRDLTARNVLVTENNVMKIADFGLARDINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLT

来源 Source

来源生物 organism	Homo sapiens
通用名 common_name	Human
NCBI 分类编号 ncbi_taxonomy_id	9606
宿主生物 host_organism	;Escherichia coli 'BL21-Gold(DE3)pLysS AG' ;

实体 2 Entity 2 non-polymer

描述 description	ethyl [4-({3-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazin-5-yl}sulfonyl)-1H-imidazol-1-yl]acetate
分子量 formula_weight	499.5 kDa
来源方法 src_method	man
拷贝数 entity_count	4

▼

7. 折叠分类 (SCOP + CATH) 12 domains

SCOP 2.08 (4 domains)

结构域编号 domain_id	d6agxa_
类 Class class	d — Alpha and beta proteins (a+b)
折叠类型 Fold fold	d.144 — Protein kinase-like (PK-like)
超家族 Superfamily superfamily	d.144.1 — Protein kinase-like (PK-like)
家族 Family family	d.144.1.7 — Protein kinases, catalytic subunit

结构域编号 domain_id	d6agxb_
类 Class class	d — Alpha and beta proteins (a+b)
折叠类型 Fold fold	d.144 — Protein kinase-like (PK-like)
超家族 Superfamily superfamily	d.144.1 — Protein kinase-like (PK-like)
家族 Family family	d.144.1.7 — Protein kinases, catalytic subunit

结构域编号 domain_id	d6agxc_
类 Class class	d — Alpha and beta proteins (a+b)
折叠类型 Fold fold	d.144 — Protein kinase-like (PK-like)
超家族 Superfamily superfamily	d.144.1 — Protein kinase-like (PK-like)
家族 Family family	d.144.1.7 — Protein kinases, catalytic subunit

结构域编号 domain_id	d6agxd_
类 Class class	d — Alpha and beta proteins (a+b)
折叠类型 Fold fold	d.144 — Protein kinase-like (PK-like)
超家族 Superfamily superfamily	d.144.1 — Protein kinase-like (PK-like)
家族 Family family	d.144.1.7 — Protein kinases, catalytic subunit

CATH v4.4 (8 domains)

结构域编号 domain_id	6agxA01
类 Class class	3 — Alpha Beta
架构 Architecture architecture	30 — 2-Layer Sandwich
拓扑 Topology topology	200 — Phosphorylase Kinase; domain 1
同源超家族 H-superfamily homologous superfamily	20 — Phosphorylase Kinase; domain 1

结构域编号 domain_id	6agxA02
类 Class class	1 — Mainly Alpha
架构 Architecture architecture	10 — Orthogonal Bundle
拓扑 Topology topology	510 — Transferase(Phosphotransferase); domain 1
同源超家族 H-superfamily homologous superfamily	10 — Transferase(Phosphotransferase) domain 1

结构域编号 domain_id	6agxB01
类 Class class	3 — Alpha Beta
架构 Architecture architecture	30 — 2-Layer Sandwich
拓扑 Topology topology	200 — Phosphorylase Kinase; domain 1
同源超家族 H-superfamily homologous superfamily	20 — Phosphorylase Kinase; domain 1

结构域编号 domain_id	6agxB02
类 Class class	1 — Mainly Alpha
架构 Architecture architecture	10 — Orthogonal Bundle
拓扑 Topology topology	510 — Transferase(Phosphotransferase); domain 1
同源超家族 H-superfamily homologous superfamily	10 — Transferase(Phosphotransferase) domain 1

结构域编号 domain_id	6agxC01
类 Class class	3 — Alpha Beta
架构 Architecture architecture	30 — 2-Layer Sandwich
拓扑 Topology topology	200 — Phosphorylase Kinase; domain 1
同源超家族 H-superfamily homologous superfamily	20 — Phosphorylase Kinase; domain 1

结构域编号 domain_id	6agxC02
类 Class class	1 — Mainly Alpha
架构 Architecture architecture	10 — Orthogonal Bundle
拓扑 Topology topology	510 — Transferase(Phosphotransferase); domain 1
同源超家族 H-superfamily homologous superfamily	10 — Transferase(Phosphotransferase) domain 1

结构域编号 domain_id	6agxD01
类 Class class	3 — Alpha Beta
架构 Architecture architecture	30 — 2-Layer Sandwich
拓扑 Topology topology	200 — Phosphorylase Kinase; domain 1
同源超家族 H-superfamily homologous superfamily	20 — Phosphorylase Kinase; domain 1

结构域编号 domain_id	6agxD02
类 Class class	1 — Mainly Alpha
架构 Architecture architecture	10 — Orthogonal Bundle
拓扑 Topology topology	510 — Transferase(Phosphotransferase); domain 1
同源超家族 H-superfamily homologous superfamily	10 — Transferase(Phosphotransferase) domain 1

▶

8. 引用文献 (1)

▶

晶胞边长 a length_a	88.317 Å
晶胞边长 b length_b	78.270 Å
晶胞边长 c length_c	99.251 Å
晶胞夹角 α angle_alpha	90.00 °
晶胞夹角 β angle_beta	96.47 °
晶胞夹角 γ angle_gamma	90.00 °
晶胞分子数 Z z_pdb	8

空间群 space_group	P 1 21 1
空间群编号 int_tables_number	4
晶系 crystal_system	—

分辨率 resolution	2.950 Å
最低分辨率 resolution_low	45.220 Å
R 因子 r_factor	0.2537
R_work r_work	0.2514
R_free r_free	0.2984

fit	/app/data/saxs_computation/ag/6agx/6agx.fit
pddf	/app/data/pr_computation/ag/6agx/6agx.pr.out
profile	/app/data/saxs_computation/ag/6agx/6agx.dat